Isomorphic Labs, a subsidiary of Alphabet Inc., is preparing to initiate human clinical trials for AI-developed drugs using technology from DeepMind's AlphaFold3. Founded in 2021, the company aims to leverage AI to create a general drug design engine applicable across various diseases. With the ambition to eventually address all diseases, Isomorphic Labs represents a growing trend of tech companies integrating AI into healthcare and medicine. Early advancements include improved diagnostics tools capable of outperforming human physicians in accuracy.
Isomorphic Labs is focused on creating a general drug design engine that applies AI across various disease areas, not just specific targets or modalities.
Isomorphic Labs, a London-based drug developer, aims to utilize AI in breakthrough drug discovery and ultimately strives to 'solve all diseases'.
Collection
[
|
...
]